» Articles » PMID: 11805011

Stability of 11-nor-delta(9)-carboxy-tetrahydrocannabinol Glucuronide in Plasma and Urine Assessed by Liquid Chromatography-tandem Mass Spectrometry

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2002 Jan 24
PMID 11805011
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Unconjugated 11-nor-Delta(9)-carboxy-tetrahydrocannabinol (THCCOOH) in blood and urine has been proposed as a valuable marker, but the glucuronide (THCCOOglu) is present in considerably higher concentrations than the parent drug. Acyl glucuronides have been shown to be potentially reactive conjugates, which may affect the in vitro metabolite pattern.

Methods: Extraction procedures and a liquid chromatography-tandem mass spectrometry assay were developed and validated to investigate the stability of THCCOOglu in urine and plasma. Plasma and urine samples with added THCCOOglu were stored at -20, 4, 20, and 40 degrees C up to 10 days.

Results: The glucuronide was stable at -20 degrees C in both matrices, whereas THCCOOglu concentrations decreased at all other storage conditions. For a given storage time and temperature, the decrease in plasma was higher than that in urine. At 20 degrees C, a marked change in concentration could be observed within 2 days of storage. Degradation of THCCOOglu followed an apparent first-order process and led to the formation of THCCOOH. The sum of the molar concentrations of both analytes corresponded only to the initial THCCOOglu in plasma and urine samples stored at 4 degrees C.

Conclusions: The in vitro degradation of THCCOOglu prevents clinical conclusions based on the metabolite pattern or the concentration of unconjugated THCCOOH in samples stored at > or =4 degrees C for prolonged periods.

Citing Articles

Avatar Intervention in Virtual Reality for Cannabis Use Disorder in Individuals With Severe Mental Disorders: Results From a 1-Year, Single-Arm Clinical Trial.

Giguere S, Beaudoin M, Dellazizzo L, Phraxayavong K, Potvin S, Dumais A JMIR Ment Health. 2024; 11:e58499.

PMID: 39602812 PMC: 11612600. DOI: 10.2196/58499.


Development of an LC-MS/MS method for the determination of five psychoactive drugs in postmortem urine by optimization of enzymatic hydrolysis of glucuronide conjugates.

Matsuo T, Ogawa T, Iwai M, Kubo K, Kondo F, Seno H Forensic Toxicol. 2024; 42(2):181-190.

PMID: 38557936 PMC: 11269451. DOI: 10.1007/s11419-024-00685-1.


Associations between hair-derived cannabinoid levels, self-reported use, and cannabis-related problems.

Kroon E, Cousijn J, Filbey F, Berchtold C, Binz T, Kuhns L Psychopharmacology (Berl). 2024; 241(6):1237-1244.

PMID: 38407636 PMC: 11106191. DOI: 10.1007/s00213-024-06558-0.


Avatar Intervention for Cannabis Use Disorder in Individuals with Severe Mental Disorders: A Pilot Study.

Giguere S, Potvin S, Beaudoin M, Dellazizzo L, Giguere C, Furtos A J Pers Med. 2023; 13(5).

PMID: 37240936 PMC: 10223054. DOI: 10.3390/jpm13050766.


The Association of Unfavorable Traffic Events and Cannabis Usage: A Meta-Analysis.

Hostiuc S, Moldoveanu A, Negoi I, Drima E Front Pharmacol. 2018; 9:99.

PMID: 29487531 PMC: 5816577. DOI: 10.3389/fphar.2018.00099.